Seegene, Inc (096530) Fair Value & Analysis
Healthcare · KR · Market cap 1.3T KRW
Fair value as of: Jul 20, 2026
From 24 valuation models · updated 20 days ago
Share price +2.3% over the past month.
A strong business, but screening 38% overvalued on our models.
What matters now
- A high-quality business (quality 79/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (22,514 KRW). The favourable scenario is already priced in.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 17,457 KRW – 92,702 KRW · fair‑value band 17,357 KRW – 22,514 KRW · the 28,900 KRW price screens above the 18,011 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
Seegene, Inc (096530) currently trades at 28,900 KRW, while our model-based Fair Value estimate is 18,011 KRW, implying the stock looks roughly 37.7% overvalued today. The Quality Score stands at 79/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Seegene, Inc generated revenue of 487B KRW at a net margin of 13.5%. Revenue grew 11.3% year over year. It earns a return on equity of 6.5%. Fundamentals as of Jul 20, 2026
Our scenario range runs from 17,357 KRW (bear case) to 22,514 KRW (bull case); at 28,900 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 17% below its 52-week high and 34% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -38%, 096530 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (55,753 KRW) versus Economic Profit (9,406 KRW). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 76 · Market factors (momentum, volatility) 49
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens …
Full company description
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of SNPs in factor II, factor V, and MTHFR genes. The company has a collaboration with Werfen for the joint development of syndromic qPCR assays. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Seegene, Inc reported revenue of 474B KRW in FY2025 versus 1.4T KRW in FY2021, a compound −23.3%/yr. Reported net income was 48.3B KRW in FY2025, compounding −45.2%/yr from FY2021.
096530 screens 38% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Seegene, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Seegene, Inc (096530) overvalued or undervalued?
What is the fair value of 096530?
What is the quality score of 096530?
What is the revenue of Seegene, Inc (096530)?
What is the net profit margin of 096530?
Does Seegene, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Seegene, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.